EGFR and breast carcinoma: Breast cancer cells that make too much HER2/ERBB2 spread faster but are also more likely to respond to HER-specific chemo and immunotherapy, with mutations in MUC4 known to associate with upregulated ERBB proteins, observed in the Indian cohort (Mill et al., 2011).